A live-attenuated viral vector vaccine protects mice against lethal challenge with Kyasanur Forest disease virus

Sociodemographic factors associated with Kyasanur forest disease in India - a retrospective study

Objectives

Kyasanur forest disease (KFD) is a tick-borne disease in India affecting humans and two local non-human primate species. A critical knowledge gap in the scientific literature is the lack of information on how people's sociodemographic factors influence KFD occurrence.

Methods

We analyzed available data on KFD from three data sources: (a) 104 peer-reviewed articles using keyword searches on PubMed Central and Google Scholar, (b) 116 Program for Monitoring Emerging Diseases reports, and (c) an acute febrile illness surveillance data set on KFD from a report by the government of India. We performed statistical analyses to calculate the prevalence of KFD by state and differences in KFD cases by sex and age group.

Results

All three data sets used indicate that KFD cases and deaths have occurred predominantly in the 15-64 years age group (literature: 87% cases and 95% deaths, Program for Monitoring Emerging Diseases: 78% cases and 78% deaths, acute febrile illness: 96% cases [no breakdown for acute febrile illness death data]). Data reporting varies across states and is non-standardized.

Conclusions

The inconsistent reporting of sociodemographic data on KFD in India has created a gap in our understanding of its impact on different social groups. Collecting and reporting data on sociodemographic factors is critical to understanding the epidemiology of KFD and designing effective public health interventions.

Pathogenicity of Lloviu and Bombali Viruses in Type I Interferon Receptor Knockout Mice

Type I interferon receptor knockout (IFNAR-/-) mice are not able to generate a complete innate immune response; therefore, these mice are often considered to assess the pathogenicity of emerging viruses. We infected IFNAR-/- mice with a low or high dose of Lloviu virus (LLOV) or Bombali virus (BOMV) by the intranasal (IN) or intraperitoneal (IP) route and compared virus loads at early and late time points after infection. No signs of disease and no viral RNA were detected after IN infection regardless of LLOV dose. In contrast, IP infections resulted in increased viral loads in the high-dose LLOV and BOMV groups at the early time point. The low-dose LLOV and BOMV groups achieved higher viral loads at the late time point. However, there was 100% survival in all groups and no signs of disease. In conclusion, our results indicate a limited value of the IFNAR-/- mouse model for investigation of the pathogenicity of LLOV and BOMV.

Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates

Kyasanur Forest disease virus (KFDV) is an endemic arbovirus in western India mainly transmitted by hard ticks of the genus Haemaphysalis. KFDV causes Kyasanur Forest disease (KFD), a syndrome including fever, gastrointestinal symptoms, and hemorrhages. There are no approved treatments, and the efficacy of the only vaccine licensed in India has recently been questioned. Here, we studied the protective efficacy of a vesicular stomatitis virus (VSV)-based vaccine expressing the KFDV precursor membrane and envelope proteins (VSV-KFDV) in pigtailed macaques. VSV-KFDV vaccination was found to be safe and elicited strong humoral and cellular immune responses. A single-dose vaccination reduced KFDV loads and pathology and protected macaques from KFD-like disease. Furthermore, VSV-KFDV elicited cross-reactive neutralizing immune responses to Alkhurma hemorrhagic fever virus, a KFDV variant found in Saudi Arabia.

Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model

BACKGROUND

Nipah virus (NiV) causes recurrent outbreaks of lethal respiratory and neurological disease in Southeast Asia. The World Health Organization considers the development of an effective vaccine against NiV a priority.

METHODS

We produced two NiV vaccine candidates using the licensed VSV-EBOV vaccine as a backbone and tested its efficacy against lethal homologous and heterologous NiV challenge with Nipah virus Bangladesh and Nipah virus Malaysia, respectively, in the African green monkey model.

FINDINGS

The VSV-EBOV vaccine expressing NiV glycoprotein G (VSV-NiVG) induced high neutralising antibody titers and afforded complete protection from homologous and heterologous challenge. The VSV-EBOV vaccine expressing NiV fusion protein F (VSV-NiVF) induced a lower humoral response and afforded complete homologous protection, but only partial heterologous protection. Both vaccines reduced virus shedding from the upper respiratory tract, and virus replication in the lungs and central nervous system. None of the protected animals vaccinated with VSV-NiVG or VSV-NiVF showed histological lesions in the CNS, but one VSV-NiVF-vaccinated animal that was not protected developed severe meningoencephalitis.

INTERPRETATION

The VSV-NiVG vaccine offers broad protection against NiV disease.

FUNDING

This study was supported by the Intramural Research Program, NIAID, NIH.